Log in  First Connection?

BreastArchives

RERE-AS1 as a regulator of immune modulation and therapeutic response in breast cancer
Breast
 9 min.

 Published on 23/12/2025 |  Original article (Full-text)  | Jiang Shaohui et al. | Cancer Immunology, Immunotherapy 2026; 75(1): 13

Breast cancer (BRCA) is a major malignancy among women globally. Its steadily increasing incidence and mortality impose profound physical and psychological distress on patients and families while exerting a significant socioeconomic burden [1, 2, 3–4]. In a city in China, the treatment cost for...

Paraneoplastic cochleovestibulopathy associated with breast cancer: a case report of two patients and literature review
Breast
 3 min.

 Published on 16/12/2025 |  Original article (Full-text)  | Yang Liqin et al. | BMC Neurology 2025; 25(1): 502

Paraneoplastic cochleovestibulopathy (PCVP) was first described by Greene in 2014 as an atypical form of paraneoplastic neurological syndrome (PNS) [1]. It is characterized by sudden or rapidly progressive hearing loss or vestibular dysfunction that is unresponsive to high-dose oral or intratympanic...

Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer
Breast
 7 min.

 Published on 09/12/2025 |  Original article (Full-text)  | Allsopp Rebecca C. et al. | BMC Cancer 2025; 25(1): 1856

Breast cancer (BC) is the second leading cause of death for women worldwide, with the number of incidences rising [1]. Approximately 30% of women go on to develop metastatic breast cancer (MBC) with a 5-year survival rate of 28% [2]. Intratumor heterogeneity presents the biggest therapeutic challenge,...

Macrophages in obesity-related breast cancer: mechanistic insights and therapeutic opportunities
Breast
 6 min.

 Published on 02/12/2025 |  Original article (Full-text)  | Dong Huiyu et al. | Breast Cancer Research 2025; 27(1): 209

Obesity has become a global pandemic With the World Obesity Atlas 2024 projecting that over 54% of the world's adult population will be overweight or obese by 2035 based on BMI criteria [1]. Once prevalent mainly in developed nations, this metabolic disorder is now increasingly widespread in developing...

ACSL6 modulates docosahexaenoic acid-induced cytotoxicity to potentiate chemotherapy response in colorectal and breast cancer
Breast
 8 min.

 Published on 25/11/2025 |  Original article (Full-text)  | Chen I-Sung et al. | Oncogenesis 2025; 14(1): 45

Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to adapt to microenvironmental challenges, sustain proliferation, evade immune surveillance, and develop therapeutic resistance [1]. Emerging evidence underscores the pivotal role of lipid metabolism in cancer progression, where tumor...